Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity (vol 11, pg 417, 2001)

被引：0
|
作者：
Wennerholm, A
Johansson, I
Hidestrand, M
Bertilsson, L
Gustafsson, LL
IngelmanSundberg, M
机构：
来源：
PHARMACOGENETICS | 2001年 / 11卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：743 / 743
页数：1
相关论文
共 27 条
  • [11] Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses (vol 101, pg 124, 2015)
    Varela, Nelson
    Quinones, Luis A.
    Stojanova, Jana
    Garay, Joselyn
    Caceres, Dante
    Cespedes, Silvia
    Sasso, Jaime
    Miranda, Carla
    PHARMACOLOGICAL RESEARCH, 2016, 110 : 276 - 276
  • [12] Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population (vol 46, pg 18, 2000)
    Garcia-Barceló, M
    Chow, LY
    Chiu, HFK
    Wing, YK
    Lee, DTS
    Lam, KL
    Waye, MMY
    CLINICAL CHEMISTRY, 2000, 46 (11) : 1873 - 1873
  • [13] CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. (vol 11, pg 43, 2010)
    Gaedigk, Andrea
    Fuhr, Uwe
    Johnson, Charlene
    Berard, Anick
    Bradford, L. DiAnne
    Leeder, J. Steven
    PHARMACOGENOMICS, 2010, 11 (02) : 275 - 275
  • [14] Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations (vol 66, pg 859, 2010)
    Gaedigk, Andrea
    Isidoro-Garcia, Maria
    Pearce, Robin E.
    Sanchez, Santiago
    Garcia-Solaesa, Virginia
    Lorenzo-Romo, Carolina
    Gonzalez-Tejera, Gloria
    Corey, Susan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (01) : 101 - 101
  • [15] Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics (vol 15, pg 1947, 2014)
    Tay-Sontheimer, J.
    PHARMACOGENOMICS, 2015, 16 (02) : 174 - 174
  • [16] Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics (vol 15, pg 1947, 2014)
    Tay-Sontheimer, J.
    Shireman, L. M.
    Beyer, R. P.
    PHARMACOGENOMICS, 2015, 16 (08) : 913 - 913
  • [17] Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population (vol 65, pg 570, 1999)
    Tateishi, T
    Chida, M
    Ariyoshi, N
    Mizorogi, Y
    Kamataki, T
    Kobayashi, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (06) : 581 - 581
  • [18] CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation dosages (vol 104, pg 173, 2001)
    Kirchheiner, J
    ACTA PSYCHIATRICA SCANDINAVICA, 2001, 104 (06) : 475 - 475
  • [19] Resolution of a clinical AmpliChip CYP450 Test™ no call: discovery and characterization of novel CYP2D6*1 haplotypes (vol 15, pg 1175, 2014)
    Gaedigk, Andrea
    Garcia-Ribera, Carles
    Jeong, Hye-Eun
    Shin, Jae-Gook
    Hernandez-Sanchez, Juanjo
    PHARMACOGENOMICS, 2014, 15 (11) : 1552 - 1552
  • [20] Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans (vol 5, pg 173, 2005)
    Gaedigk, A
    Bhathena, A
    Ndjountché, L
    Pearce, RE
    Abdel-Rahman, SM
    Alander, SW
    Bradford, LD
    Leeder, JS
    PHARMACOGENOMICS JOURNAL, 2005, 5 (04): : 276 - 276
123